Tekla Life Sciences Investors

NYSE:HQL

Asset Management

Financial Services
$19.27 +0.62%

+$0.11 today

Market cap
$585.96M
Beta
0.73
P/E (TTM)
2.8
EPS (TTM)
$6.52
Dividend yield
11.35%
52W Low $12.34High $18.46

Volume 0.12M

Average 0.11M

HQL EBITDA Margin

EBITDA as a percentage of revenue.

Tekla Life Sciences InvestorsNYSE: HQL

EBITDA Margin · Q2 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to 135.9%

EBITDA Margin was 135.9% in Q2 FY2026, up 395.5 pp from a year earlier. Over 3 fiscal years it widened by 418.0 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
135.9%— QoQ
Last fiscal yearSep 2025
99.1%-1.5 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+395.5 pp——
1 year-1.5 pp——
3 years+418.0 pp——
5 years——
10 years——

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
99.1%
Year-over-year change
-1.5pp

EBITDA Margin vs competitors

How HQL compares with its peers on the latest reported figures

  • HQL's FY2025 EBITDA Margin of 99.1% is the 3rd highest of the 10 companies compared; the peer median is 48.4%.
  • Its year-over-year change of -1.5 pp is the 5th highest of 10, against a peer median of -2.8 pp.
  • Over three fiscal years its change of +418.0 pp compares with a peer median of +31.5 pp.
HQL Competitors Peer median
EBITDA Margin for HQL and competitors
Company Period LTM level YoY 3-year change
SORSource Capital, Inc.FY2025135.3% +38.0 pp+293.4 pp
GAINGladstone Investment CorporationLTM Mar 2026118.5% +45.1 pp+217.4 pp
HQLTekla Life Sciences InvestorsFY202599.1% -1.5 pp+418.0 pp
PNNTPennantPark Investment CorporationLTM Mar 202696.3% +47.6 pp+113.3 pp
GLADGladstone Capital CorporationLTM Mar 202671.5% -9.9 pp-27.6 pp
MCIBarings Corporate InvestorsLTM Jun 202548.4% -37.8 pp+31.5 pp
CCAPCrescent Capital BDC, Inc.LTM Mar 202640.9% -2.8 pp+34.3 pp
CIONCION Investment CorporationLTM Mar 202618.4% +32.8 pp-15.7 pp
ECCEagle Point Credit Company Inc.LTM Dec 2025-50.8% -50.5 pp-204.8 pp
TCPCBlackRock TCP Capital Corp.LTM Mar 2026-388.5% -268.6 pp-79.5 pp
Peer median (excluding HQL) 48.4%-2.8 pp+31.5 pp

Competitors are the stored peer set for HQL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Revenue45.02M31.86M39.39M86.69M86.39M
Cost of Revenue6.08M5.55M5.24M5.36M4.97M
Gross Profit38.95M26.31M18.28M86.69M86.39M
Gross Margin86.5%82.6%46.4%100.0%100.0%
Research & Development0(3)000
Selling, General & Admin844.02K1.08M903.14K1.33M743.17K
Operating Expenses1.16M1.35M1.17M1.39M791.57K
Depreciation & Amortization4.14M2.99M27.6M1.92M0
EBITDA68.68M(101.62M)49.95M87.22M85.59M
EBITDA Margin152.5%-318.9%126.8%100.6%99.1%
Operating Income64.53M(104.6M)(5.24M)85.3M85.59M
Operating Margin143.3%-328.3%-13.3%98.4%99.1%
Interest Income050.09K204.45K1.04M349.84K
Interest Expense00000
Other Income / Expenses(7.83K)2.42K27.6M87.22M0
Income Before Tax64.53M(104.6M)22.35M85.3M85.59M
Pre-Tax Margin143.3%-328.3%56.8%98.4%99.1%
Income Tax Expense00000
Net Income64.53M(104.6M)22.35M85.3M85.59M
Net Margin143.3%-328.3%56.8%98.4%99.1%
EPS (Basic)2.66(4.07)0.793.042.96
EPS (Diluted)2.66(4.07)0.793.042.96
Weighted Avg Shares24.26M25.68M28.29M28.06M28.87M
Weighted Avg Shares (Diluted)24.26M25.68M28.29M28.06M28.87M

Tekla Life Sciences Investors

NYSE:HQL

Intrinsic Alpha fair value

Locked

Current Price

$19.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.